Clinical trials: Cholangiocarcinoma Cancer
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver and Biliary Tumor Tissue Registry
Patients having surgery to remove a liver or biliary tissue mass or having a biopsy of a mass or lesion will have a tissue sample collected and stored for future research of liver and biliary diseases.
- Trial name
- NCT02917759
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mayo Clinic
Metastatic Cholangiocarcinoma, Cholangiocarcinoma
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma (CCA) or pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Metastatic Cholangiocarcinoma, Cholangiocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT03250273
- Testing
- Entinostat, Nivolumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intrahepatic Cholangiocarcinoma
HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC
This study is a single-arm Phase II clinical trial aiming to evaluate the safety and efficacy of HAIC combined with Cadonilimab and Regorafenib as second-line treatment for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06335927
- Testing
- HAIC-GEMOX+Cadonilimab+Regorafenib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
This study evaluates the efficacy and safety of second-line treatment of bortezomib in advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive bortezomib while the other half will receive best…
- Trial name
- NCT03345303
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhengang Yuan
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and…
- Trial name
- NCT00919061
- Testing
- Gemcitabine, Cisplatin, Sorafenib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Cholangiocarcinoma
Deep Liver Phenotyping and Immunology Study
Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide.
- Trial name
- DELPHI (NCT04946773)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Oxford
Cholangiocarcinoma, Liver Neoplasms
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
This pilot clinical trial studies the safety and effectiveness of continuous hepatic arterial infusion (HAI) of floxuridine (FUDR) alone or in combination with other chemotherapeutic drugs in treating patients with locally…
- Trial name
- NCT01525069
- Testing
- Floxuridine, Dexamethasone, Gemcitabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Cholangiocarcinoma, Bile Duct Neoplasms
Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
This is the prospective observational study to explore whether the SpyGlass DS II system could be used to screen early-stage neoplastic bile duct lesions in selected patients.
- Trial name
- NCT05600803
- Testing
- Single-operator cholangioscopy
- Where
- South Korea
- Volunteers
- 236 people
- Sponsor
- Soonchunhyang University Hospital
Cholangiocarcinoma
Trial of IRE in Cholangiocarcinoma
The purpose of this study is to test any good and bad side effects of surgery using IRE to treat cancer of the bile duct.
- Trial name
- NCT03769753
- Testing
- IRE Device
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer of the Gallbladder, Cancer of the Biliary Tract
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
This is a Phase II trial of the combination of oxaliplatin (Eloxatin) and capecitabine (Xeloda), known as XELOX, in participants with unresectable or recurrent cholangiocarcinoma, including carcinoma of the gallbladder or biliary…
- Trial name
- NCT00338988
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Cholangiocarcinoma
An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma
After enrollment, they received photodynamic therapy and sonodynamic therapy for a maximum of 2 times, and the longest treatment time was 6 months.The investigator will judge whether the second photodynamic therapy+ sonodynamic…
- Trial name
- NCT05580328
- Testing
- Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Cholangiocarcinoma
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
To evaluate the safety and tolerability of HAIC combined with donafenib and sintilimab in first-line treatment of unresectable ICC.
- Trial name
- NCT05348811
- Testing
- HAIC combined with donafenib and sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhongda Hospital
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Cholangiocarcinoma
Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients
This is an observational study intended to validate results of a previous study done at the Mayo Clinic. Patients are treated with combination chemotherapy and radiation and maintained on oral Xeloda until they can receive liver…
- Trial name
- NCT00301379
- Testing
- Observation data collection study.
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Washington University School of Medicine
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic…
- Trial name
- FIDES-01 (NCT03230318)
- Testing
- derazantinib
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 148 people
- Sponsor
- Basilea Pharmaceutica
Colorectal Cancer Metastatic to Liver, Intrahepatic Cholangiocarcinoma
Infusion System for Hepatic Cancer
This is a single-site, open-label continued access study/treatment protocol under a treatment IDE. In addition to treating patients, the primary objective of this study is to assess the safety of using the Medtronic SynchroMed II…
- Trial name
- NCT04684862
- Testing
- Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ronald DeMatteo, M.D.
HCC - Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively.
- Conditions
- HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT07106827
- Testing
- GV20-0251
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
BTC
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
The primary objective is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) combined with GemOX and lenvatinib as conversion therapy for Initially…
- Trial name
- NCT07263360
- Testing
- Iparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cholangiocarcinoma
Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. It is the second-most common liver cancer, after hepatocellular carcinoma (HCC).
- Trial name
- cholangio (NCT03042182)
- Testing
- Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
- Where
- 2 sites in Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Cholangiocarcinoma
The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma
The investigators found an inverse relationship between CD24 and MiR-122 levels. Then the investigators found that CD24 that goes up with MiR-122 down makes macrophages unable to engulf the tumor cells. All this in mice.
- Trial name
- CD24CCA (NCT06707025)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.